Pfizer and BioNTech announced this week that they are seeking an emergency use authorization from the FDA for an additional booster dose of their COVID-19 vaccine for older adults.
The companies have submitted an application for the EUA for adults aged 65 years or older who have already received a booster dose of any authorized COVID-19 vaccine.
Their submission was based on data from Israel that showed an additional dose of the vaccine increases immunogenicity, lowers rates of confirmed infections and lowers rates of severe illness, according to a press release.
One analysis by the Israeli